These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19801101)

  • 41. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
    Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
    Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.
    Maki H; Hojo K; Tanaka H; Sawada TY; Maekawa R; Yoshioka T
    Clin Exp Metastasis; 2002; 19(6):519-26. PubMed ID: 12405289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation of Ultrasound Shear Wave Elastography with Pathological Analysis in a Xenografic Tumour Model.
    Elyas E; Papaevangelou E; Alles EJ; Erler JT; Cox TR; Robinson SP; Bamber JC
    Sci Rep; 2017 Mar; 7(1):165. PubMed ID: 28279018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation.
    Cunningham D
    Eur J Cancer; 1996; 32A Suppl 3():S1-8. PubMed ID: 8943658
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
    Cao S; Rustum YM
    Cancer Res; 2000 Jul; 60(14):3717-21. PubMed ID: 10919639
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
    Masi G; Falcone A; Di Paolo A; Allegrini G; Danesi R; Barbara C; Cupini S; Del Tacca M
    Clin Cancer Res; 2004 Mar; 10(5):1657-63. PubMed ID: 15014016
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
    Vassal G; Boland I; Santos A; Bissery MC; Terrier-Lacombe MJ; Morizet J; Sainte-Rose C; Lellouch-Tubiana A; Kalifa C; Gouyette A
    Int J Cancer; 1997 Sep; 73(1):156-63. PubMed ID: 9334824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
    Nukatsuka M; Nakagawa F; Saito H; Sakata M; Uchida J; Takechi T
    Anticancer Res; 2015 Mar; 35(3):1437-45. PubMed ID: 25750295
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Irinotecan in the first-line treatment of colorectal cancer.
    Saltz LB
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):54-8. PubMed ID: 9726092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
    Hanrahan EO; Lin HY; Kim ES; Yan S; Du DZ; McKee KS; Tran HT; Lee JJ; Ryan AJ; Langmuir P; Johnson BE; Heymach JV
    J Clin Oncol; 2010 Jan; 28(2):193-201. PubMed ID: 19949019
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
    Ikeguchi M; Arai Y; Maeta Y; Ashida K; Katano K; Wakatsuki T
    Surg Today; 2011 Sep; 41(9):1196-9. PubMed ID: 21874414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma.
    Jansen WJ; Kolfschoten GM; Erkelens CA; Van Ark-Otte J; Pinedo HM; Boven E
    Int J Cancer; 1997 Dec; 73(6):891-6. PubMed ID: 9399672
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
    Ducreux M; Köhne CH; Schwartz GK; Vanhoefer U
    Ann Oncol; 2003; 14 Suppl 2():ii17-23. PubMed ID: 12810453
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intestinal permeability in colorectal cancer patients treated by raltitrexed or irinotecan.
    Melichar B; Dvorák J; Kohout P; Melicharová K; Solichová D; Zadák Z
    J Clin Gastroenterol; 2003 Aug; 37(2):192-3. PubMed ID: 12869896
    [No Abstract]   [Full Text] [Related]  

  • 58. CPT-11 in gastrointestinal cancer.
    Bleiberg H
    Eur J Cancer; 1999 Mar; 35(3):371-9. PubMed ID: 10448285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor.
    Morales C; Zurita M; Vaquero J
    J Neurooncol; 2002 Feb; 56(3):219-26. PubMed ID: 12061727
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages.
    Bruns CJ; Shinohara H; Harbison MT; Davis DW; Nelkin G; Killion JJ; McConkey DJ; Dong Z; Fidler IJ
    Cancer Res; 2000 Jan; 60(1):2-7. PubMed ID: 10646841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.